Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Comparison of cost-effectiveness of once-monthly oral ibandronate vs. weekly oral alendronate in female patients with osteoporosis

  • At: 2013 FIP Congress in Dublin (Ireland)
  • Type: Poster
  • By: DEMETI, Arlinda (Bio-Parafarmacia Franceze, Tirana, Albania)
  • Co-author(s): Miraci, Mirela (Faculty of Pharmacy in University of the Medical Sciences, Tirana, Albania)
    Zicishti, Mira (Neo-Style clinic, Tirana, Albania)
    Vukani, Besa (Neo-Style clinic, Tirana, Albania)
    Shehi, Agim (Institute of Hygiene and Epidemiology, Tirana, Albania)
    Mata, Elida (Institute of Hygiene and Epidemiology, Tirana, Albania)
    Pasho, Ina (Vitrina University, Tirana, Albania)
  • Abstract:

    Backgr.: Osteoporosis (ops) affects the quality of life, increases health care costs, increases the number of sick days and can be a very painful disease. It can be treated with alendronate (aln) or ibandronate (ibn). Cost of illness as well as effectiveness of ibn vs. aln in patients (pts) with ops has been assessed in our previous studies..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses